Shinichiro Kurosawa, MD, PhD
Associate Professor of Pathology and Laboratory MedicineBoston University School of Medicine Kurosawa@bu.edu
Objective: My overall goal is to bring new therapeutics and novel diagnostics to patients through our pre-clinical non-human primate models of human diseases.
Key words: Clinical Hematology, Critical Care Medicine, Blood Coagulation and Inflammation, Sepsis and Septic Shock, Pre-clinical in vivo models,
Biodefense Pathogens, Hemolytic Uremic Syndrome, Disseminated Intravascular coagulation
Highlights of Key experiences: My background includes sets of experience to conduct translational research.
- Served as a member of the central evaluation committee for Phase II and Phase III multi-center clinical trials.
- PI for conducting the clinical trials within the institutions.
- Seven plus years of Consultative Hematology experience, focusing on the abnormalities in hemostasis and coagulation. About half of the patients were at the Intensive/Critical care units.
- Conducted basic investigation of structure-function relationship analyses of Protein C anti-coagulant pathway members at the molecular levels.
- Group leader in the Primate research, where research was performed in an investigational ICU setting.
Research Interests In the Translational Research:
Our laboratory focuses on studying host responses in the field of translational medicine. We have established multiple pre-clinical in vivo models. We continue our efforts to establish, standardize and validate models, so that the system will help provide means for filling the gap between bench and bedside. Most recently, we are applying high throughput technology to evaluate host responses at molecular level. The results from our models frequently feed back to the basic research and vice versa, providing us unique sets of hypotheses. The availability of the model and the novel hypotheses will give our students and postdoctoral fellows a unique advantage. We can also help our collaborators, who have proved the concept using mouse models, by moving the project beyond rodent biology. We are committed to bring new diagnostics and therapeutics in order to improve/save human lives.
I Hold three patents concerning novel diagnostic approaches. One of which was successfully licensed to a French diagnostic company, and now commercially available. If the critical findings are not properly protected as intellectual properties, it is unlikely that the technology will benefit patients down the line.